QuintilesIMS Changes Name to IQVIA

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-12-06-2017
Volume 12
Issue 12

QuintilesIMS has changed its name to IQVIA to reflect its October 2016 merger with IMS Health.

On Nov. 6, 2017, QuintilesIMS announced that it has changed its name to IQVIA, and will operate as a contract research services provider specializing in technological and analytical solutions for life sciences and healthcare companies. Starting Nov. 15, 2017, equity shares of the company will trade on the New York Stock Exchange under the new name and new ticker symbol “IQV.”

According to the company, the rebranding resulted from the merger of QuintilesIMS and IMS Health, announced in May 2016 and completed in October 2016.

“Today is a defining moment for our organization as we introduce a new name that aligns with our vision to help stakeholders drive healthcare forward,” said IQVIA CEO and chairman Ari Bousbib, in a company press release. “Our clients have been instrumental in our becoming IQVIA. IMS Health and Quintiles came together because our clients were asking for better, faster ways to bring innovations to patients and capture the improvements the industry has been pursuing for years. Since the merger, we’ve worked to integrate our capabilities in advanced analytics, leading technologies and therapeutic expertise into powerful, differentiated offerings.”

Following this rebranding, the company, comprising of 55,000 employees in more than 100 countries, plans to advance its human data science capabilities with a focus on improving clinical development, data security, and privacy protection through its services.

Source: IQVIA

Recent Videos
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content